tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Dysuria D053159 1 associated lipids
Nocturia D053158 1 associated lipids
Delayed Graft Function D051799 2 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Diabetes Complications D048909 4 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Hyperuricemia D033461 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Lacerations D022125 1 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Qi S et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. 2003 Transplantation pmid:12717189
Haririan A et al. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. 2003 Transplantation pmid:12717201
Abbott KC et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. 2005 Transplantation pmid:16340779
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Sampaio MS et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. 2012 Transplantation pmid:22129761
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
Winkler ME et al. Successful pregnancy in a patient after liver transplantation maintained on FK 506. 1993 Transplantation pmid:7506460
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Garcia-Criado FJ et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. 1998 Transplantation pmid:9798713
Mack-Shipman LR et al. Reproductive hormones after pancreas transplantation. 2000 Transplantation pmid:11063337
Chisholm MA et al. Renal transplant patient compliance with free immunosuppressive medications. 2000 Transplantation pmid:11063348
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Mourad G et al. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. 2017 Transplantation pmid:27547871
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Gaber AO et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Transplantation pmid:19005398
Atkison PR et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. 1997 Transplantation pmid:9311719
Hoogduijn MJ et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. 2008 Transplantation pmid:19005411
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Baid-Agrawal S et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. 2004 Transplantation pmid:15114085
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Lang T et al. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. 1997 Transplantation pmid:9415561
Marino IR et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. 2004 Transplantation pmid:15385809
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Stevens RB et al. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. 2015 Transplantation pmid:25083614
McDevitt-Potter LM et al. A multicenter experience with generic tacrolimus conversion. 2011 Transplantation pmid:21788920
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Ravaioli M et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. 2015 Transplantation pmid:25757214
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Suzuki S et al. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. 1993 Transplantation pmid:7685932
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Pascual M et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. 1998 Transplantation pmid:9869086
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Krook H et al. Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection process. 2002 Transplantation pmid:12438951
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Baran DA et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 Transplantation pmid:12438960
Blaheta RA et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. 2000 Transplantation pmid:10830246
Vafadari R et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. 2012 Transplantation pmid:22643331
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Morales JM et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. 2008 Transplantation pmid:18724234
Opelz G and Döhler B Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. 2008 Transplantation pmid:18698238
Gallon LG et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. 2007 Transplantation pmid:17519781
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Higgins R et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. 2009 Transplantation pmid:19300192
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Steiner RW Steroid withdrawal in kidney transplantation: the subgroup fallacy. 2011 Transplantation pmid:21336084
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Jain AB et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. 2003 Transplantation pmid:14501862
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Hricik DE et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2002 Transplantation pmid:12151730
Ueki S et al. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. 2006 Transplantation pmid:17198266
Ogawa H et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. 2002 Transplantation pmid:12151737
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
MacDonald AS Impact of immunosuppressive therapy on hypertension. 2000 Transplantation pmid:11152235
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Sher LS et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. 1997 Transplantation pmid:9256184
Yuzawa K and Fukao K Topical FK506 ointment for skin grafting. 1998 Transplantation pmid:9565111
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Younes BS et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. 2000 Transplantation pmid:10919581
Higgins RM et al. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10919600
Cherikh WS et al. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. 2003 Transplantation pmid:12923430
Zieliński A et al. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. 2003 Transplantation pmid:12923442
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Krämer BK et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. 2012 Transplantation pmid:22858806
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575